78% of moderate aortic stenosis patients have high-risk features that double mortality and heart failure hospitalization risk within two years, study shows.
Eton Pharma's ET-900 program tests mecasermin injection for refractory infantile spasms, with first patient dosing planned for Q1 2027.
PROSpect's phase 3 RCT enrolled 424 children with PARDS and found neither prone positioning nor HFOV improves ventilator-free ...
Regulatory gaps and organizational challenges slow AI adoption in clinical trials despite proven 90% reductions in data ...
CluePoints positions RBQM architecture as the structural foundation for clinical monitoring, consolidating evidence across ...
Zhimeng Biopharma completes enrollment of CB03-154 Phase 2/3 ALS trial with 255 patients across China, targeting Q3 2027 ...
Novartis's pelacarsen hit its Lp(a) target in 8,323 patients but missed the cardiovascular endpoint entirely, exposing a $6B ...
The PROSpect trial found neither prone positioning nor HFOV improved ventilator-free days in PARDS, and the trial design that ...
ASP-1929 + Pembrolizumab achieved 28.2-month median OS in recurrent/metastatic HNSCC, with 35% alive at four years in Phase ...
PharPoint Research joins Medrio's Early Adopter Program to shape clinical trial management system design before product ...
Moleculin Biotech completes dosing in Phase 2/3 MIRACLE trial for AnnAraC in relapsed/refractory AML, with full data expected ...
Hengrui Pharma presents 64 studies at ESMO 2026, a record for the Chinese oncology company showcasing 14 approved innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results